...
首页> 外文期刊>Assay and drug development technologies >A Pharmacochaperone-Based High-Throughput Screening Assay for the Discovery of Chemical Probes of Orphan Receptors
【24h】

A Pharmacochaperone-Based High-Throughput Screening Assay for the Discovery of Chemical Probes of Orphan Receptors

机译:基于药物基于药物的高通量筛选测定,用于发现孤儿受体的化学探针

获取原文
获取原文并翻译 | 示例
           

摘要

G-protein-coupled receptors (GPCRs) have varying and diverse physiological roles, transmitting signals from a range of stimuli, including light, chemicals, peptides, and mechanical forces. More than 130 GPCRs are orphan receptors (i.e., their endogenous ligands are unknown), representing a large untapped reservoir of potential therapeutic targets for pharmaceutical intervention in a variety of diseases. Current deorphanization approaches are slow, laborious, and usually require some in-depth knowledge about the receptor pharmacology. In this study we describe a cell-based assay to identify small molecule probes of orphan receptors that requires no a priori knowledge of receptor pharmacology. Built upon the concept of pharmacochaperones, where cell-permeable small molecules facilitate the trafficking of mutant receptors to the plasma membrane, the simple and robust technology is readily accessible by most laboratories and is amenable to high-throughput screening. The assay consists of a target harboring a synthetic point mutation that causes retention of the target in the endoplasmic reticulum. Coupled with a beta-galactosidase enzyme-fragment complementation reporter system, the assay identifies compounds that act as pharmacochaperones causing forward trafficking of the mutant GPCR. The assay can identify compounds with varying mechanisms of action including agonists and antagonists. A universal positive control compound circumvents the need for a target-specific ligand. The veracity of the approach is demonstrated using the beta-2-adrenergic receptor. Together with other existing assay technologies to validate the signaling pathways and the specificity of ligands identified, this pharmacochaperone-based approach can accelerate the identification of ligands for these potentially therapeutically useful receptors.
机译:G蛋白偶联受体(GPCR)具有不同且不同的生理作用,从一系列刺激透射信号,包括光,化学物质,肽和机械力。超过130gPCR是孤儿受体(即,它们的内源性配体未知),代表了各种疾病中药物干预的潜在治疗靶标的大型未开发的储层。目前的除臭方法缓慢,费力,并且通常需要一些关于受体药理学的深入知识。在该研究中,我们描述了基于细胞的测定,以鉴定不需要先验的受体药理学的孤儿受体的小分子探针。基于药物橡胶的概念,其中细胞可渗透的小分子促进突变受体对血浆膜的贩运,大多数实验室易于访问简单且稳健的技术,并且可用于高通量筛选。该测定由含有合成点突变的靶标,导致内质网中的靶标。结合β-半乳糖苷酶 - 片段片段互补报告系统,该测定鉴定了作为药物橡胶酮导致突变GPCR发挥发挥作用的化合物。测定可以鉴定具有不同作用机制的化合物,包括激动剂和拮抗剂。通用阳性对照化合物避免需要靶特异性配体。使用β-2-肾上腺素能受体证明该方法的真实性。与其他现有的测定技术一起验证信号通路和所鉴定的配体的特异性,这种基于药物基于药物的方法可以加速这些潜在治疗有用受体的配体的鉴定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号